Quick Answer
Arcutis Biotherapeutics, Inc. reported Net Income Loss of -$16.14 million for the year ending 2025.
- Arcutis Biotherapeutics, Inc. showed an increase of +88.5% in Net Income Loss from 2024 to 2025.
- This data is from Arcutis Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$6.66 million | Q2 2019: -$8.29 million | Q3 2019: -$14.48 million | Q4 2019: -$12.57 million | Q1 2020: -$28.01 million | Q2 2020: -$35.41 million | Q3 2020: -$38.20 million | Q4 2020: -$34.05 million | Q1 2021: -$36.04 million | Q2 2021: -$42.01 million | Q3 2021: -$56.98 million | Q1 2022: -$64.32 million | Q2 2022: -$67.41 million | Q3 2022: -$107.71 million | Q1 2023: -$80.10 million | Q2 2023: -$70.99 million | Q3 2023: -$44.77 million | Q1 2024: -$35.38 million | Q2 2024: -$52.33 million | Q3 2024: -$41.54 million | Q1 2025: -$25.06 million | Q2 2025: -$15.89 million | Q3 2025: $7.41 million.
- Over the full 8 years of available data (2018 to 2025), Arcutis Biotherapeutics, Inc.'s Net Income Loss has grown by 16.2%.
- Historical annual values: Fiscal year 2025: -$16.14 million | Fiscal year 2024: -$140.04 million | Fiscal year 2023: -$262.14 million | Fiscal year 2022: -$311.46 million | Fiscal year 2021: -$206.36 million | Fiscal year 2020: -$135.68 million | Fiscal year 2019: -$42.00 million | Fiscal year 2018: -$19.26 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: